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Correction {#jah34878-sec-0001}
==========

In the article by Huang et al, "Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non--Vitamin K Antagonist Oral Anticoagulants or Warfarin," which published online January 10, 2020, and appeared in the January 21, 2020 issue of the journal (*J Am Heart Assoc*. 2020;9:e013845. DOI: [10.1161/JAHA.119.013845](10.1161/JAHA.119.013845)), a correction was needed.

###### 

Comparison for the Risk of Osteoporosis in Patients Treated With NOACs Versus Warfarin in the Sensitivity Analyses

                            Sensitivity Analysis A[a](#jah34878-note-0002){ref-type="fn"}   Sensitivity Analysis B[b](#jah34878-note-0003){ref-type="fn"}   Sensitivity Analysis C[c](#jah34878-note-0004){ref-type="fn"}                                 
  ------------------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- --------- ------------------- ---------
  NOAC vs warfarin                                                                                                                                                                                                                                        
  NOAC overall              0.85 (0.73--0.99)                                               0.031                                                           0.84 (0.74--0.95)                                               0.007     0.83 (0.68--1.01)   0.066
  Warfarin                  1.00 (Reference)                                                                                                                1.00 (Reference)                                                          1.00 (Reference)    
  Rivaroxaban vs warfarin                                                                                                                                                                                                                                 
  Rivaroxaban               0.71 (0.59--0.85)                                               \<0.001                                                         0.65 (0.54--0.78)                                               \<0.001   0.64 (0.51--0.81)   \<0.001
  Warfarin                  1.00 (Reference)                                                                                                                1.00 (Reference)                                                          1.00 (Reference)    
  Dabigatran vs warfarin                                                                                                                                                                                                                                  
  Dabigatran                1.07 (0.90--1.27)                                               0.461                                                           1.05 (0.87--1.27)                                               0.601     1.06 (0.86--1.31)   0.588
  Warfarin                  1.00 (Reference)                                                                                                                1.00 (Reference)                                                          1.00 (Reference)    
  Apixaban vs warfarin                                                                                                                                                                                                                                    
  Apixaban                  0.55 (0.34--0.90)                                               0.016                                                           0.40 (0.22--0.71)                                               0.002     0.41 (0.20--0.84)   0.015
  Warfarin                  1.00 (Reference)                                                                                                                1.00 (Reference)                                                          1.00 (Reference)    

HR indicates hazard ratio; NOAC, non--vitamin K antagonist oral anticoagulant.

Sensitivity analysis A was conducted by including all the eligible patients for analyses without performing propensity score matching.

Sensitivity analysis B was conducted by performing propensity score matching with replacement (nearest‐neighbor matching with replacement) before analyses.

Sensitivity analysis C was conducted by excluding patients who had rheumatic heart disease, who had congenital heart disease, or who had undergone valve replacement surgery before analyses.

The HRs were calculated using multivariable Cox proportional hazard regression models adjusted for all baseline characteristics shown in [Table 1](#jah34878-tbl-0001){ref-type="table"}.
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In Table [5](#jah34878-tbl-0001){ref-type="table"}, the first column of the p values, for Sensitivity Analysis A, was incorrectly set under the column heading "Sensitivity Analysis B." The corrected version is shown below.

The publisher regrets the error.

The online version of the article has been updated and is available at <https://www.ahajournals.org/doi/full/10.1161/JAHA.119.013845>
